Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HY0001a in Advanced Solid Tumors
NCT07069062Phase 2Recruiting
- Sponsor
- Sichuan Huiyu Pharmaceuticals
- Start
- Jul 2025
- Primary completion
- Jun 2027
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of HY0001a in solid tumor, esophageal cancer, non-small cell lung cancer (NSCLC) and 6 more, sponsored by Sichuan Huiyu Pharmaceuticals. Primary endpoints: Dose-Limiting Toxicity at 21 days, Treatment-Emergent Adverse Events at 2 years and 1 more. Started Jul 2025; status: recruiting.
02
Drugs
HY0001a
03
Conditions
solid tumoresophageal cancernon-small cell lung cancer (NSCLC)Cervical Cancer (CC)squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT07069062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07069062.